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Abstract 
Background 
The novel fourth-generation cryoballoon (CB4) potentially allows for enhanced catheter 
maneuverability and more frequent capture of pulmonary vein (PV) potentials which can be used to 
monitor real-time PV isolation. Aim of our study is to compare the acute procedural endpoints 
between the CB4 and second-generation cryoballoon (CB2). 
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Methods 
A single-center retrospective chart review was used to examine 50 consecutive patients with drug-
refractory atrial fibrillation undergoing CB4-based pulmonary vein isolation (PVI). Procedural data 
and acute success of these patients were compared to 50 propensity- matched controls who 
underwent cryoballoon ablation procedure using CB2. 
 
Results 
Procedures performed with the CB4 showed significant shorter fluoroscopy time (14.8 ± 5.5 vs 18.0 ± 
6.5 min, p = 0.04), shorter procedure time (58.3 ± 15.7 vs 65.3 ± 21 min, p = 0.13), and shorter total 
ablation time (10.8 ± 1.5 vs 13.8 ± 1.9 min, p = 0.42). The real –time PVI visualization rate was 33.3% 
in CB2 group and 74.7% in CB4 group (p <0.001). CB4 was correlated to significant increase of acute 
real- time recordings with regard to all the single PV (left superior PV: 58% vs 84%, p= 0.02; left 
inferior PV: 26% vs 71%, p= 0.001; right superior PV 29% vs 61%, p= 0.01; and right inferior PV 19% 
vs 58%, p= 0.002). 
 
Conclusion 
The CB4 was more often able to capture real-time recordings of PV potentials and the subsequent 
acute PV isolation.  
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1. Introduction 
As a cornerstone technique, pulmonary vein isolation (PVI) is the primary target for catheter 
ablation in patients with drug-refractory symptomatic paroxysmal and persistent atrial fibrillation 
(AF)(1). Furthermore, the cryoballoon (CB) catheter is a well-described tool that has achieved good 
procedural results with a freedom from AF recurrence that is similar to radiofrequency ablation 
catheters (2). Particularly, since 2012, the second-generation CB (CB2, Artic Front Advance, 
Medtronic, Inc., Minneapolis, MN, USA) has been described as a catheter with a high procedural 
success rate and durability of clinical outcomes in the treatment of patients with AF(3-7). Recent 
technical changes were completed to improve the CB catheter in terms of maneuverability and 
pulmonary vein (PV) signal recordings during PVI. The resulting fourth-generation CB (CB4, Artic 
Front Advance PRO, Medtronic, Inc., Minneapolis, MN, USA) is characterized by a shorter tip (8 mm 
distal tip versus 13.5 mm tip of the traditional balloon; a 40% reduction) that can potentially 
facilitate better visualization of PV signals (Figure 1).  
The real-time visualization of PV potentials allows for a patient-tailored ablation strategy. 
Specifically, the visualization of time-to-effect (TTE; defined as the duration of freeze until acute 
circumferential cellular electrical dormancy is achieved) can be utilized to define a freeze duration at 
each individual PV. In practice, TTE is the time from the beginning of the freeze application until the 
moment the PV is electrically isolated.  Consequently, the routine usage of TTE can potentially avoid 
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extra freeze-cycle(s) and predict longer-term clinical outcome such as AF recurrence (as a predictive 
clinical parameter of outcomes) (7-11). Here, the objective of the current study is to assess and 
compare the first acute procedural data using the novel CB4 compared to the CB2. 
 
2. Material and methods 
2.1 Patient population.  
Consecutive patients with drug-refractory paroxysmal or persistent AF scheduled for an 
index CB-base ablation by PVI method at our Institution (from November 2017 to February 2019) 
were retrospectively analyzed. Procedures performed between November 2017 and September 
2018 were done with the CB2 catheter; whereas, those ablations between October 2018 and 
February 2019 were performed using the CB4 catheter. The procedural data of 50 patients treated 
with the CB4 technology (CB4-group) were collected and compared to propensity-matched patients 
treated with the second-generation CB (CB2-group) technology. The data collection and study design 
complied with the Declaration of Helsinki. 
 
2.2 Procedural management. 
Before the procedure, transesophageal echocardiography was performed to rule out 
intracardiac thrombi (if clinically indicated). Novel oral anticoagulants were stopped at most 12 
hours prior the procedure; whereas, vitamin-K antagonists were continued with an INR around two.  
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All patients provided informed consent before the procedure, and all procedures were performed by 
experienced operators (beyond the well-established learning curve). 
At the start of the catheter ablation procedure, deep sedation was established using a bolus 
of fentanyl and a continuous infusion of propofol. The cryoablation procedure has been described in 
detail in previous studies (3, 6). Briefly, a single transseptal puncture was performed using a 
transseptal needle system (BRK, Abbott, Minneapolis, MN, USA) and a standard sheath (SL0 8-Fr, 
Abbott, MN, USA). The transseptal sheath was exchanged over a guidewire for a 12-Fr steerable 
sheath (FlexCath Advance, Medtronic, Minneapolis, MN, USA). Thereafter, the balloon was advanced 
into the left atrium (LA) guided by the inner-lumen diagnostic mapping catheter (Achieve Advance, 
20 mm diameter, Medtronic, Inc., Minneapolis, MN, USA). Heparin was administered intravenously 
as a bolus followed by a continuous infusion. An esophageal temperature probe was used in all 
patients (Esotherm, FIAB) to monitor luminal temperature.  
After the CB was inflated and maneuvered to the antra surface of the PV; a contrast 
injection was completed to assess the PV occlusion. The Achieve catheter was positioned proximally 
to visualize PV potential recordings. TTE was recorded and defined as the time from cryoablation 
initiation until the last recorded PV potential signal. All procedures were guided by TTE, and under 
the TTE guidance protocol, four individualized dosing methodologies were defined. Initially, if PVI 
was obtained within the first-freeze application and TTE was <40 sec; then a “short-freeze” protocol 
was performed (which continued the freeze-cycle until a total ablation time of 180 sec). If TTE was 
between 40 and 120 sec, then a “no-bonus- freeze” protocol was used (which entailed a standard 
freeze-cycle duration of 240 sec without an additional bonus-freeze-cycle). In a third option, if TTE 
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was >120 sec, a “bonus- freeze” protocol was selected (which continued the freeze-cycle for 240 sec 
and followed the freeze with an additional bonus-freeze-cycle of 180 sec or 240 sec duration, 
depending on the operator preference). Finally, if the TTE could not be visualized, then the freeze-
cycle duration was set to a standard freeze-cycle of 240 sec, and an extra freeze was done according 
to physician’s opinion. 
As usual in our Center, during right-sided PV cryoablations, continuous phrenic nerve (PN) 
pacing (1200 msec cycle; 10mA, 2 ms) was performed using a diagnostic catheter to electrically pace 
the PN at a level above the superior vena cava. Freeze energy delivery was interrupted immediately 
if weakening or loss of diaphragmatic contraction was noted by tactile feedback or was observed 
under fluoroscopic imaging. Acute PVI was confirmed by demonstrating entry and exit block with the 
Achieve mapping catheter placed in each vein, and another freeze was performed if acute PV 
reconnection occurred.  
 
2.3 Statistical Analysis 
This was an observational, single-center study, and to reduce bias due to patient baseline 
clinical characteristics, a propensity-score matching analysis was performed to account for critical 
differentiating patient variables, including: gender, age, hypertension, body mass index (BMI), LA 
volume, previous antiarrhythmic drug(s) usage, and type of AF. During statistical analyses, 
continuous variables were reported as mean ± standard deviation, and comparisons of continuous 
variables were performed using the independent sample Student’s t-test. Categorial variables were 
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presented as frequency or percentage and were compared by Fisher’s exact test. The ANOVA test 
was performed to assess the differences between continuous, normally distributed data for two 
groups, and the Mann-Whitney test was used otherwise. Statistical significance was considered with 
a 𝑝-value of <0.05. Lastly, SPSS v.19.0 statistical software (IBM Corp., Armonk, NY, USA) was used for 
statistical analysis. 
 
3. Results 
In our study, 50 patients underwent CB4 catheter PVI (CB4-group). Previously, 545 patients 
underwent PVI ablation with CB2 catheter, and a propensity-score matching with the CB2 group left 
50 patients for analysis with the CB4 group.  In total, 100 patients underwent CB ablation at Centro 
Cardiologico Monzino IRCCS, in Milan, Italy, and these patients were evaluated in our retrospective 
study. As the two groups were propensity-score matched, the baseline clinical characteristics in 
terms of age, gender, type of AF, BMI, LA volume were all similar. Also, no significant differences 
were found between the two study groups regarding CHA2DS2-VASc score and other baseline 
medical recordings. Baseline patient characteristic data for both CB2 and CB4 groups are provided in 
Table 1.  
 
3.1 Procedural results of CB2 and CB4 groups 
Acute success and procedural data are reported in Table 2. Compared to CB2 ablations, 
procedures performed with the CB4 showed significant shorter fluoroscopy time (14.8 ± 5.5 vs 18.0 ± 
  
 
 
This article is protected by copyright. All rights reserved. 
9 | P a g e            Comparison of 2°and 4°-generation cryoballoons              
M o l t r a s i o  e t  a l .  
 
6.5 min, p = 0.04), shorter procedure time (58.3 ± 15.7 vs 65.3 ± 21 min, p = 0.13), and shorter total 
ablation time (10.8 ± 1.5 vs 13.8 ± 1.9 min, p = 0.42).  A total of 389 of 389 PVs (100%) were 
identified and successfully isolated (195 PVs in CB2 group and 194 in CB4 group).  Balloon nadir 
temperature was significantly higher in the CB4 group only for the left superior PV (-49.8 ± 5.6 vs -
45.6 ± 6.7 °C, p = 0.01) and the left inferior PV (- 47.7 ± 5.2 vs -43.2 ± 5.6 °C, p = 0.002).  Real-time 
PVI was visualized in 33.3% of the PVs in CB2 group and 74.7% of PVs in CB4 group (p < 0.001), using 
the Achieve Advance catheter in both groups. As shown in Figure 2, there was a significant 
difference with regard to all the single PV acute TTE recordings between the two groups (left 
superior PV: 58% vs 84%, p= 0.02; left inferior PV: 26% vs 71%, p= 0.001; right superior PV 29% vs 
61%, p= 0.01; and right inferior PV 19% vs 58%, p= 0.002). In addition, the frequency of recording 
TTE in Left Common PV was greater using CB4 than using CB2, without reaching statistical 
significance (75% vs 33%, p=0.37). Significant difference in total cryo-applications number were 
founded between the two groups (1.2 ± 0.43 in CB2 vs 1.1 ± 0.31 in CB4; p= 0.01). Transient PN palsy 
occurred in 3 (6%) patients in CB2 group and in 2 (4%) patients in CB4 group (p=0.50) with full 
recovery of nerve function before the hospital discharge. No severe complications occurred in both 
groups as reported in Table 2. 
 
 4. Discussion  
To the best of our knowledge, this study is the first comparison of acute clinical outcomes of 
CB2 and CB4 in patients underwent first PVI for AF. A case report from our group described the first 
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case of the CB4 PVI, reporting the feasibility of the procedure, the acute success, and the TTE 
visualization for all 4 PVIs(12).  
Our findings suggest that CB2 and CB4 have similar acute success in obtaining PVI.  Peri-
procedural complication rates were low and equivalent in both groups. Mean procedure and 
fluoroscopy times were shorter in the CB4 group. Moreover, total cryo-applications number was 
significantly reduced in CB4 procedures. Finally, CB4 significantly increased the possibility of reading 
the TTE, regardless the different PV anatomy. 
 
4.1 Acute Procedural outcomes. 
In recent times, the cryoablation is increasingly used in the electrophysiology laboratories 
for the treatment of patients with AF.  Technological developments have allowed an easier 
maneuverability of the cryoballoon inside the LA and a greater possibility of reading the electrical 
signals of the pulmonary veins due to a proximal position of the Achieve catheter. Mainly, AF 
cryoablation procedures performed with CB4 showed a better visualization of real-time vein signals 
(74.7% vs 33.3%), providing evidence for acute PVI. The significant improvement in TTE detection 
was observed in all veins. These results confirm previously published data regarding the third-
generation cryoballoon (CB3, Arctic Front Advance ST, Medtronic, Inc., Minneapolis, MN, USA) that 
was withdrawn from the commercial market due to higher balloon nadir temperatures probably 
caused by a more proximal positioning of the intra-balloon thermocouple (13-15). In our population, 
the main reason for failure to obtain TTE recordings was the distal placement of the Achieve in order 
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to guarantee balloon stability especially in right inferior pulmonary veins (TTE displayed CB2 vs CB4, 
19% vs 58% respectively, p= 0.002). This result could be also explained by the typically shorter PV 
sleeves extension around the inferior pulmonary veins (16). 
Moreover, the possibility to measure TTE allows the physician to significantly reduce 
fluoroscopy time, probably because the PV signals confirm the correct position of the balloon during 
the initial freeze cycle and led to a lesser use of fluoroscopy to guide the operators. More 
importantly, TTE enables the user to tailor the PVI procedure personalizing the number of freeze(s). 
In our study total cryo-applications number was significantly lower in CB4 group, probably because 
the TTE visualization allowed to avoid extra freeze cycles. Ferrero-de-Loma-Osorio et al. proposed a 
new individualized protocol, based on TTE plus 60- and a 120-sec bonus freezes, which led to shorter 
procedure times and similar AF recurrence at 1-year follow-up (17, 18). 
In our current study, procedure and total ablation time were also decreased by the use of 
the CB4 catheter probably due to a greater ability to record PV electrograms and real time TTE that 
enhance the procedural efficacy by reducing the number of total cryo-applications and as a 
consequence the total procedure and ablation time. From previous reports, procedural times in 
cryoablation PVI largely ranged from 60 to 160 minutes (7, 17-20) and depended on several factors, 
including: the experience of the operator, the volume of caseloads of the center, the choose PVI 
protocol in terms of number and durations of freezes, and the method of verification of PV 
reconnections.  
Despite the internal cryoballoon structure has not been modified, the nadir temperature 
resulted to be significantly higher in CB4 group during cryoenergy delivery, especially for the 
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superior and inferior left PVs. It is important to know that the temperature was measured by the 
thermocouple located on the proximal part of the balloon and provided information about balloon- 
tissue contact. Then, our finding could be explained by several independent variables such as the 
balloon position within the PV ostium (proximal/distal), balloon to PV diameter ratio and balloon 
manipulation by the operator.  
Finally, in our experience the CB4 provided a similar rate of acute PVI in comparison to 
previous CB2. However, larger and multicenter studies are needed to better evaluate if the CB4 
could improve both acute- and longer-term clinical outcomes.  
 
5. Limitations  
Our study has some limitations. First, it is not a prospective randomized trial. Although the 
two groups were propensity-score matched so that the baseline characteristics were similar, a 
possible confounding effect of unknown variables cannot be excluded.  
Secondly, it is a single-center study and the number of enrolled patients was relatively small. These 
findings have to be confirmed by larger multicenter experiences and randomized studies. 
Thirdly, it cannot be a blind study due to structural differences between the two cryo-catheters. 
Lastly, only acute efficacy and safety data are provided while long term clinical outcome will need 
future assessment.  
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6. Conclusions 
The novel CB4 has been designed to improve the recording of real-time PV signals during 
balloon PVI. The availability of a shorter tip leads to a significant increase in the observation rate of 
TTE. An increase in TTE observation rate permits a tailored procedure approach and a reduction in 
fluoroscopy time and procedure duration.  
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FIGURE LEGENDS 
Figure 1. 
Primary changes of the fourth-generation cryoballoon catheter compared to the second- generation. 
Panel A) Second-generation Arctic Front Advance cryoballoon with longer distal tip (13 mm). Panel 
B) Fourth-generation Arctic Front Advance PRO was designed to have a shorter tip (8mm) in order to 
allow more proximal placement of the spiral mapping catheter in the pulmonary vein and increase in 
the ability to visualize real-time pulmonary vein recording(s) during ablation. 
 
 
 
 
Figure 2. 
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The percentage of real time pulmonary vein recording(s) during the procedure per vein according to 
the cryoballoon generation that was utilized. 
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Table 1.  Clinical baseline characteristics of the study population. Continuous data presented as 
mean and standard deviation. Categorical data given as number count and percentage. 
 Overall 
(N=100) 
CB2 
(N=50) 
CB4 
(N=50) 
p-
Value 
Baseline Variables     
     Age (years)  59.7 ± 12.1 59.4 ± 13.2 60.0 ± 11.2 0.84 
     Female gender 28 (28) 16 (32) 12 (24) 0.25 
     Hypertension 58 (58) 32 (64) 26 (52) 0.15 
     Diabetes mellitus 7 (7) 2 (4) 5 (10) 0.22 
     Body Mass Index (Kg/m2) 26.2 ± 5.7 27.3 ± 7.4 25.1 ± 2.9 0.56 
     Prior TIA/Stroke 6 (6) 3 (6) 3 (6) 0.66 
     Obstructive sleep apnea 14 (14) 5 (10) 9 (18) 0.19 
     Chronic renal failure 0 (0) 0 (0) 0 (0) - 
     CHA2DS2-VASc 1.5 ± 1.2 1.6 ± 1.3 1.3 ± 1.2 0.36 
     EHRA Classification 2.1 ± 0.6 2.2 ± 0.6 2.1 ± 0.5 0.41 
     Persistent AF status 20 (20) 12 (24) 8 (16) 0.23 
     Coronary artery disease 9 (9) 6 (12) 3 (6) 0.24 
Echocardiographic Variables     
     Left Atrial volume (ml/mq) 38.8 ± 11.7 39.1 ± 11.9 38.6 ± 11.7 0.86 
     Left Ventricular EF (%) 60.5 ± 8.4 59.5 ± 9.5 61.5 ± 7.1 0.34 
Baseline medical therapy     
     Amiodarone 16 (16) 7 (14) 9 (18) 0.39 
     Antiarrhythmic drugs (Class I) 84 (84) 42 (84) 42 (84) 0.61 
     Beta blockers 38 (38) 19 (38) 19 (38) 0.61 
Abbreviations: TIA= transient ischemic attack, EHRA= European heart rhythm association, EF= 
ejection fraction, AF= atrial fibrillation. 
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Table 2. Procedural data, acute success, and complications. Intra-procedural cryoballoon ablation 
data in all population and according to the second- and fourth-generation cryoballoon usage. 
Continuous data presented as mean and standard deviation. Categorical data given as number 
count and percentage. 
 Overall 
(N=100) 
CB2 
(N=50) 
CB4 
(N=50) 
p-Value 
Procedural data     
     Procedure time (min) 61.8 ± 18.7 65.3 ± 21.0 58.3 ± 15.7 0.13 
     Fluoroscopy time (min) 16.4 ± 6.2 18.0 ± 6.5 14.8 ± 5.5 0.04 
     Total ablation time (min) 12.3 ± 2.3 13.8 ± 1.9 10.8 ± 1.5 0.42 
     Left Atrial dwell time (min) 44.7 ± 11.3 46.6 ± 11.9 42.9 ± 10.5 0.20 
     Number of PVs 389/389 (100) 195/195 (100) 194/194 (100) - 
     Number of PVs isolated 389/389 (100) 195/195 (100) 194/194 (100) - 
     Number of  Left Common PV 7/7 (100) 3/3 (100) 4/4 (100) - 
     Rate of PVI recordings 210/389 (54.0) 65/195 (33.3) 145/194 (74.7) < 0.001 
     Total freeze cycles until PVI 1.2 ± 0.38 1.2 ± 0.43 1.1 ± 0.31 0.01 
Time-to-effect     
     Left Common PV (sec) 47.4 ± 21.2 44.3 ± 22.5 49.7 ± 23.4 0.62 
     Left Superior PV (sec) 47.8 ± 24.5 49.3 ± 28.5 46.1 ± 21.4 0.67 
     Left Inferior PV (sec) 42.8 ± 24.7 43.5 ± 31.1 42.5 ± 22.5 0.32 
     Right Superior PV (sec) 36.9 ± 30.6 39.3 ± 46.7 35.7 ± 20.7 0.77 
     Right Inferior PV (sec) 40.6 ± 24.2 36.5 ± 19.4 42.1 ± 25.9 0.56 
Temperature at isolation     
      Left Common PV (°C) -37.1 ± 2.8 -37.3 ± 3.0 -37.0 ± 3.2 0.80 
     Left Superior PV (°C) -36.2 ± 7.9 -33.0 ± 9.1 -37.5 ± 6.6 0.07 
     Left Inferior PV (°C) -32.6 ± 9.6 -28.8 ± 8.8 -33.7 ± 9.2 0.18 
     Right Superior PV (°C) -33.3 ± 8.4 -31.2 ± 8.8 -34.3 ± 8.2 0.37 
     Right Inferior PV (°C) -32.2 ± 8.1 -30.3 ± 5.9 -32.8 ± 8.7 0.51 
Nadir balloon temperature     
      Left Common PV (°C) -45.8 ± 1.8 -46.0 ± 1.7  45.7 ± 2.2 0.52 
     Left Superior PV (°C) -47.8 ± 6.5 -45.6 ± 6.7 -49.8 ± 5.6 0.01 
     Left Inferior PV (°C) -45.6 ± 5.8 -43.2 ± 5.6 - 47.7 ± 5.2 0.002 
     Right Superior PV (°C) -48.1 ± 6.4 -47.4 ± 7.4 -48.8 ± 5.2 0.37 
     Right Inferior PV (°C) -45.7 ± 5.9 -45.0 ± 6.3 -46.4 ± 5.6 0.36 
Procedure-related 
complications 
    
     Acute PNP 5 (5) 3 (6) 2 (4) 0.50 
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     Pericardial effusion 1 (1) 1(2) 0 (0) 0.50 
     Cardiac tamponade 0 (0) 0 (0) 0 (0) - 
     Cerebral embolization 0 (0) 0 (0) 0 (0) - 
     Vascular injury 1 (1) 0 (0) 1 (2) 0.50 
Abbreviations: PV= pulmonary vein, PVI= pulmonary vein isolation, PNP= phrenic nerve palsy 
 
 
